Multiple myeloma refractory to lenalidomide: A systematic literature review of trials and real‐world evidence

Ähnliche Einträge

• Benefit of selinexor dose reduction on outcomes with selinexor, bortezomib and dexamethasone in patients with lenalidomide‐refractory multiple myeloma: Subgroup analysis of the BOSTON trial
  von: Sosana Delimpasi, et al.
  Veröffentlicht: (2026)
• Teclistamab for relapsed refractory multiple myeloma patients on dialysis
  von: P. Lebreton, et al.
  Veröffentlicht: (2024)
• Efficacy and safety of idecabtagene vicleucel in patients with relapsed–refractory multiple myeloma not meeting the KarMMa‐1 trial eligibility criteria: A real‐world multicentre study
  von: Danai Dima, et al.
  Veröffentlicht: (2024)
• Twice‐weekly induction with ixazomib–lenalidomide–dexamethasone (IRd) combination followed by extended IRd consolidation and lenalidomide maintenance in transplant‐eligible patients with newly diagnosed multiple myeloma: Results of the phase 2 study IFM2014‐03
  von: Aurore Perrot, et al.
  Veröffentlicht: (2024)
• Acalabrutinib in combination with rituximab and lenalidomide in patients with relapsed or refractory follicular lymphoma: Results of the phase 1b open‐label study ( ACE ‐ LY ‐003)
  von: Paolo Strati, et al.
  Veröffentlicht: (2024)